Tenderwize
Wróć do wyszukiwania

Open House Pharmaceutical Rebate Contracts Timolol and Tafluprost (ATC S01ED70)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 03, 2027 · 371 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Timolol und Tafluprost, ATC S01ED70

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

30 / 100

Czynniki ryzyka

The open-house contract can be automatically terminated if a conventional rebate contract for Timolol/Tafluprost comes...

Incorrect submission format (e.g., scanning without qualified signature, missing original copies) can delay contract st...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Non-exclusive discount agreements (Rabattverträge) for pharmaceutical products with active substances Timolol and Tafluprost (ATC S01ED70) under § 130a Abs. 8 SGB V.
Pokaż pełne podsumowanie

This is an open-house model for non-exclusive pharmaceutical rebate agreements (Rabattverträge) for the active substances Timolol and Tafluprost (ATC S01ED70) with AOK Bayern. Unlike a traditional tender, all eligible pharmaceutical enterprises can enter into identical, non-negotiable contracts during the window until 2027-09-03. The contracts run from 2025-11-01 to 2027-10-31. No award criteria apply; participation is open to all qualified pharmaceutical companies. The estimated contract value is not disclosed. The notice explicitly states this is not a procurement procedure under EU procurement law but an open-house model.

Ryzyka

The open-house contract can be automatically terminated if a conventional rebate contract for Timolol/Tafluprost comes...

Incorrect submission format (e.g., scanning without qualified signature, missing original copies) can delay contract st...

Kluczowe wymagania

Technical

  • Only pharmaceutical enterprises (pharmazeutische Unternehmen) may participate.

Certifications

  • Documents must be submitted in German (or with certified German translation).

Administrative

  • Submission either in paper form (2 original copies signed by hand) or electronically with qualified electronic signature via the DTVP communication area.

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open House Pharmaceutical Rebate Contracts Timolol and Tafluprost (ATC S01ED70)

Non-exclusive discount agreements for pharmaceutical products containing Timolol and Tafluprost (ATC S01ED70). Contract conclusion possible from 2025-11-01 to 2027-09-03. All contracts end on 2027-10-31. Subject to automatic termination if a nationwide or regional rebate contract (open procedure) for the same active substance takes effect.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Oct 2025 - Oct 2027

Kategoria

Pharmaceutical products

Termin

Deadline Sep 03, 2027

Szczegóły zamówienia

Data publikacji
14 Sep 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
599161-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30